Business Wire

Pyramid Analytics and Smollan forge international partnership

Share

Global retail specialists Smollan have formalised an international reseller and implementation partnership agreement with next-generation decision and business intelligence (BI) software provider Pyramid Analytics. The agreement will see Smollan, via its data and technology business, DataOrbis, expanding its current service offering to include the ability to both sell Pyramid Analytics licenses and implement Pyramid Analytics software.

“Our clients operate in incredibly competitive industries, where the ability to make the best decision, quickly is the key to strong performance. Our hunt for a BI solution that delivers superior functionality, excellent value, and next-generation capability led us to Pyramid Analytics. We migrated the majority of our DataOrbis solutions onto their software last year, and already our clients are noticing a step-change in how we can help them capitalise on the explosive amount of data they have at their fingertips,” said James Collett, Smollan’s Chief Executive: Data & Technology.

The Pyramid Analytics partnership also provides DataOrbis with a growth opportunity geared at expanding DataOrbis’ services and footprint into verticals outside of the fast-moving consumer goods (FMCG) space where they have traditionally played. This is further supported by DataOrbis and Smollan’s global footprint, which includes operations in all major gateways.

“DataOrbis has an excellent understanding of what it takes to implement a successful data strategy across an organisation, regardless of industry. We are incredibly excited to be partnering with them internationally. By leveraging their global presence throughout their client and partner networks, I believe DataOrbis, together with Pyramid Analytics, can streamline and optimise their data analytics ecosystems to prepare them for what’s next. We are thrilled to have them on board,” said Omri Kohl, Pyramid Analytics CEO.

The Pyramid Platform consistently receives top ratings among leading analyst firms that evaluate business intelligence and analytics technologies. Most recently, Pyramid earned top rankings from Gartner in the 2023 Critical Capabilities for Analytics and Business Intelligence Platforms report, including #1 for Business Analyst Use Case, #1 for Augmented Consumer Use Case, #2 for Data Scientist Use Case, and #4 for Analytics Developer Use Case.

The Pyramid Platform consolidates data preparation, business analytics, and data science into a single, integrated, self-service platform that can be accessed by all levels of data users.

“The time it takes for a decision-maker to access data can make or break a company’s competitive advantage. Pyramid Analytics reduces the amount of time it takes users across the organisation to easily find the information they need without having to request it from IT. It’s a win-win for both users and overly stretched IT departments,” said Kohl.

Implementation is key to success

As the need to unlock the power of data has accelerated, businesses are realising the benefit of having one enterprise BI platform across the organisation, ensuring a single source of truth that can be safely, securely, and ethically managed. As an early adopter, DataOrbis has invested in creating and upskilling several Pyramid Analytics’ implementation teams working out of South Africa, India, and Slovenia to assist clients in creating and implementing their own unique global views. These teams, with over 50 certified Pyramid Analytics specialists, include senior resources with expertise across industries and geographies.

The choice of BI platform is one part of the insights puzzle. The skill and time needed to implement the software is the next piece. In our experience, most companies don’t have these two vital resources readily available. By partnering with DataOrbis we can ensure the Pyramid Analytics software is expertly implemented and used to its fullest potential—all based on global best-practises. I am excited by the opportunities the Pyramid Analytics partnership will unlock for us and our clients,” said Collett.

ABOUT

Pyramid Analytics

Pyramid Analytics is the next generation of business analytics. The award-winning Pyramid Decision Intelligence Platform empowers people with augmented, automated, and collaborative insights that simplify and guide the use of data in decision-making. Critically, the Pyramid Analytics Platform operates directly on any data, enabling governed self-service for any person, and meeting analytical needs in a no-code environment without data extraction. It combines data prep, business analytics, and data science into one frictionless platform to empower anyone with intelligent decision-making. This enables a strategic, enterprise-wide approach to business intelligence and analytics, from the simple to the sophisticated. Schedule a demo. To find out more about Pyramid Analytics contact pr@pyramidanalytics.com.

Smollan

Founded in 1931, Smollan is a global commerce business, delivering growth for retailers and brand owners across five continents. Influencing what, when, where and shoppers browse and buy across multiple touchpoints, through Sales & Merchandising, Activation & Experience, Data & Technology and Digital Commerce. Internationally recognised for our exceptional human platform of over 75 000 people and our sophisticated systems, we drive sales and create brilliant shopper experiences for some of the world’s most loved brands. We are a global business that helps retailers and brands win at the point of purchase. Contact us at www.smollan.com.

DataOrbis

A leading data and technology company, DataOrbis uses its SMART ecosystem of services, solutions and technology to expertly help companies transform into businesses driven by data. With over 50 blue-chip clients, DataOrbis currently processes over 300 sources of data across 60+ countries in multiple languages. In 2020, DataOrbis joined forces with global retail specialist Smollan, increasing its ability to scale, expand and network globally.

DataOrbis is headquartered in South Africa with offices and partners across the globe. To find out more about DataOrbis contact us here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Pete Vomocil
Senior Vice President, Global Marketing, Pyramid Analytics
E-Mail: pr@pyramidanalytics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye